70% of people believe at least one divisive health claim. Science needs a new playbook

Edelman’s 2026 Trust and Health report finds 70% of 16,000 respondents across 16 countries believe at least one of six divisive health claims, highlighting a broad trust problem in health communication. Confidence in people’s ability to make informed health decisions fell 10 points to 51% in one year, while AI, peers, and social media are increasingly displacing medical expertise. The article is primarily a commentary on public trust and communication strategy rather than a market-moving event.

Analysis

The market implication is less about any single healthcare name and more about a trust-regime shift that redistributes economic power away from credentialed institutions toward platforms, intermediaries, and brands that can translate complexity into repeated, low-friction reinforcement. That favors consumer-facing healthcare businesses with strong direct channels, patient support, and education flywheels, while commoditized providers and therapeutics with weak differentiation face higher friction in adoption and retention. The second-order winner is likely AI-enabled health information and workflow tooling, but only if it is embedded in trusted distribution rather than marketed as a standalone expert replacement.

Near term, the biggest risk is not regulation or reimbursement, but conversion decay: even high-quality products can see slower uptake when the buying process requires trust-building across multiple touchpoints. That raises CAC and lengthens payback periods for digital health, telehealth, medtech launches, and elective-care demand, especially over the next 1-4 quarters as consumers continue to triangulate advice across doctors, peers, and AI. In contrast, companies with recurring engagement, brand loyalty, or caregiver adjacency can compress that trust gap and gain share from weaker competitors.

The contrarian angle is that this is not uniformly bearish for healthcare; it may be bullish for firms that acknowledge uncertainty and sell process, not certainty. Consensus underestimates how much “explainability” becomes monetizable in healthcare: companies that make trial design, safety tradeoffs, and outcome probabilities legible can improve conversion even without better efficacy. The overdone trade would be shorting the whole healthcare complex on the premise of generalized mistrust; the underdone trade is a long/short around trust architecture and distribution strength, not scientific quality alone.

Key Decisions for Investors

• Long ISRG vs short a basket of lower-trust elective/digital-health exposures over 3-6 months: ISRG benefits from clinician-led adoption and high switching costs, while weaker brands face longer sales cycles and higher education burden.
• Long VEEV or IQV on a 6-12 month horizon: infrastructure that improves explainability, patient communication, and workflow transparency should see budget resilience as providers try to rebuild trust and reduce friction.
• Short TDOC on rallies, 1-2 quarter horizon: telehealth is structurally exposed to trust disintermediation because conversion depends on repeated reassurance and weak loyalty economics; risk/reward improves if engagement metrics soften.
• Pair long LLY/LLY calls vs short a basket of mid-cap biopharma with weaker retail education brands over 6-9 months: companies with durable patient support and direct-to-consumer storytelling should outperform in a skeptical adoption environment.
• Buy out-of-the-money calls on GOOGL or MSFT for 12 months as a hedge on AI health-query monetization: if consumers keep outsourcing health interpretation to AI, trusted platforms gain engagement share; risk is regulatory scrutiny or poor model credibility.